Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Codexis turns its CodeEvolver breakthroughs into revenue isn’t easy—R&D tax credits, milestone payments, and multi-year licensing deals sprawl across hundreds of pages. If you have ever wondered, “Codexis SEC filings explained simply,” you are not alone.
Stock Titan’s AI pinpoints what matters in every document the moment it hits EDGAR. Need the Codexis quarterly earnings report 10-Q filing? We highlight enzyme-sale trends, cash-burn ratios, and collaboration revenue on a single dashboard. Curious about Codexis insider trading Form 4 transactions? Real-time alerts surface each executive stock move so you can spot patterns before the market reacts.
Our coverage spans every form:
- 10-K: Access the Codexis annual report 10-K simplified with side-by-side AI summaries that flag R&D capitalization, royalty streams, and liquidity notes.
- 10-Q: Drill into quarter-over-quarter enzyme margin shifts through our Codexis earnings report filing analysis.
- 8-K: Material agreements for ECO Synthesis scale-up? See them under Codexis 8-K material events explained.
- Form 4: Follow Codexis executive stock transactions Form 4 with real-time push updates; or search full history via Codexis Form 4 insider transactions real-time.
- DEF 14A: The Codexis proxy statement executive compensation section compares equity grants to peer biotech benchmarks.
Whether you need to model enzyme royalty cash flows, monitor financing covenants, or simply understand Codexis SEC documents with AI, our platform turns dense language into clear, actionable insights—so you spend minutes, not hours, finding the details that move the stock.
Codexis, Inc. (CDXS) received a Form 4 filing from Opaleye Management Inc., a 10% beneficial owner, detailing an open-market purchase completed on 27 June 2025.
- Transaction: 100,000 shares of Codexis common stock were purchased (Code P) at an average price of $2.39 per share.
- Post-transaction holdings: Opaleye now reports 12,350,000 shares held indirectly through Opaleye, L.P. and an additional 250,000 shares in a separately managed account, bringing total reported beneficial ownership to 12.6 million shares.
- Ownership form: All shares are reported as indirect (Form I); the investment manager disclaims beneficial ownership beyond its pecuniary interest.
- Reporting party status: Opaleye is classified as a 10% owner; no board or executive role is indicated.
The filing signals incremental insider accumulation by a large shareholder. While the 100 k-share purchase is modest relative to the 12.35 million-share position, fresh buying can be interpreted by investors as a vote of confidence in Codexis at current price levels. No derivative transactions, sales or options were disclosed in this filing.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What is Codexis Inc known for?
How does Codexis generate its technology solutions?
Which industries benefit from Codexis' enzymatic solutions?
What makes the ECO Synthesis platform significant?
How does Codexis differentiate itself from competitors?
What are the benefits of using Codexis' enzymatic solutions?
